June 10, 2026
The annual Hettleman Prizes have been awarded to promising faculty members who exemplify groundbreaking and innovative research, including UNC Lineberger members Daniel Dominguez, PhD, and Carmina G. Valle, PhD, MPH.
June 9, 2026
UNC Lineberger's Ronit Freeman, PhD, and Yevgeny Brudno, PhD, were inducted as fellows of the American Institute for Medical and Biological Engineering, one of the highest honors for researchers in this field. Four UNC faculty members received the honor.
April 29, 2026
Kristy Ainslie, PhD, and colleagues were awarded a $12.8 million NIH Program Project grant to form a collaborative team researching biomaterials to boost the body’s own immune system to enhance cell-based immunotherapy to fight glioblastoma.
April 29, 2026
Rebecca Berlow, PhD, will receive more than $2 million in NIH funding to continue exploration of a kind of protein that can contribute to cancer, heart disease, and diabetes.
April 10, 2026
David Drewry, PhD, and colleagues have been working to revolutionize the discovery and development of affordable medicines for diffuse intrinsic pontine glioma, an aggressive cancer that primarily affects young children.
April 2, 2026
The prestigious honor recognizes biochemist Jean Cook, PhD, and her work on cancer development and the human cell cycle, a biological process crucial for development, healing, and continued maintenance of the body.
March 11, 2026
Kirsten Bryant, PhD, has been awarded a $100,000 seed grant for her project that seeks to define and target metabolic changes associated with RAS inhibition in pancreatic ductal adenocarcinoma.
February 10, 2026
A dime-sized technology could transform CAR-T therapy by creating a simpler, more affordable procedure that targets many cancer types and can be done at almost any hospital.
December 15, 2025
Eleven UNC Lineberger Comprehensive Cancer Center members were named as 2025 Highly Cited Researchers by Clarivate for publishing some of the most influential scientific papers during the past decade.
December 1, 2025
UNC Eshelman School of Pharmacy’s Chemical Biology and Medicinal Chemistry Division is a central hub for cancer therapeutics. Its faculty members are studying the chemical and biological mechanisms that promote cancer growth and persistence.